Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

majakblue (< 20) Submitted: 12/13/2007 3:22:27 PM : Start Price: $23.34 RIGL Score: +61.03

Looks like an artificial run-up to raise money for a company that is bleeding funds into research and has no income from products to cover. Any revenues are probably the result of meeting milestones for collaborators who will reap the bulk of the profits if eventually a product results. Currently they have no product. Nothing in phase III trials. Do not buy at this price ($22/share). Actually, I wouldn't buy in at any price unless they had several products in Phase III and at least one product on the market. Even then you should assume that this is a very long shot and are looking for extremely high risk stocks in the hope that you will make concomitantly high gains.

PressBoard (< 20) Submitted: 10/9/2007 10:26:41 PM : Start Price: $10.10 RIGL Score: +14.34

Long leads on drug development mean this player will likely underperform the market until they have a winner make it to commercialization.

Curleyjack (< 20) Submitted: 8/30/2007 6:34:52 PM : Start Price: $9.14 RIGL Score: -12.01

A turn around coming?

StockTalking (20.97) Submitted: 8/17/2007 2:18:28 PM : Start Price: $9.80 RIGL Score: -19.84

Above the 50-day. New green bar. Biotech.

http://mystockmistakes.blogspot.com/